Shionogi announced on Wednesday that it filed for approval of its experimental influenza treatment peramivir in Japan.

The regulatory filing, which the company said was the first for the drug in any market, seeks approval for use of the intravenous neuraminidase inhibitor in patients with seasonal influenza, and also those at high risk.

Reference Articles

BioCryst partner files to market flu drug in Japan - (Birmingham Business Journal)

Shionogi seeks approval to sell flu drug in Japan - (Bloomberg)

Shionogi: applied for approval of peramivir in Japan - (CNBC)

Shionogi filed a new drug application for peramivir, a novel anti-viral drug for influenza - (Shionogi)